Innovent Bio hopes for plus-sized profits from obesity drug 信達生物維持營收目標 重點布局心血管代謝藥
The biopharmaceutical company reported a surge in half-year revenues but logged a bigger net loss, as investors look ahead to the launch of its new weight-loss drug. 這家生物藥制造商上半年總收入增加46.3%，其中藥品銷售帶來的產品收入達38.11億元，同比大增55.1%。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.